Table 2.
Biochemistry, imaging, bronchoscopy, and pathology findings in bronchial NET patients diagnosed, treated, or followed-up at our institution from 1st January 1995 to 31st December 2015 (n = 46). Treatment refers to surgery, chemotherapy, or radiotherapy.
| Parameter | Number of patients (%) |
|---|---|
| Chromogranin A (plasma) | Pre-treatment 0 (0%) |
| Post-treatment 1 (2.2%) | |
| Ki-67 (histology) | 16 (34.8%) |
| Mitotic count (histology) | 27 (58.7%) |
| Synaptophysin (histology) | 28 (60.9%) |
| Chromogranin A (histology) | 25 (54.3%) |
| CD56 (histology) | 11 (23.9%) |
| Bronchoscopy | Pre-treatment 46 (100%) |
| Post-treatment 4 (8.7%) | |
| CT | Pre-treatment 46 (100%) |
| Post-treatment 30 (65.2%) | |
| Chest X-ray | Pre-treatment 46 (100%) |
| Post-treatment 43 (93.5%) | |
| 18F-FDG PET | Pre-treatment 18 (39.1%) |
| Post-treatment 0 (0%) | |
| Octreoscan | Pre-treatment 4 (8.7%) |
| Post-treatment 2 (4.3%) |
n: number of patients.